Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCRT followed by Fruquintinib plus Sintilimab in advanced mCRC
NCT06195670Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fruquintinib in colorectal adenocarcinoma (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoints: Objective Response Rate and Progression-free Survival. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
fruquintinib
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT06195670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06195670.